Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Wild-type p53-induced phosphatase 1 (Wip1) is a member of the protein phosphatase 2C family, which is characterized by distinctive oncogenic properties. Overexpression of Wip1 is observed in certain types of human tumors that are associated with significantly poor prognosis. This study aimed to detect the expression of Wip1 in gliomas and to analyze its prognostic value in the patients. Wip1 mRNA and protein expression profiles in 81 gliomas and 15 normal brain tissues were detected using RT-PCR, Western blot and immunohistochemistry. The specimens were stained with proliferating cell nuclear antigen (PCNA) and p53 and evaluated using immunohistochemistry. Detailed clinical and demographic information of patients were retrospectively collected until 5years post-operation. Kaplan-Meier survival and Cox's regression analyses were performed to evaluate the prognosis of patients. Wip1-positive expression was observed in the majority of glioma tissues, whereas no Wip1 expression was detected in the normal brain tissues. Wip1-positive expression significantly correlated with glioma histological grade. The PCNA index was higher in the Wip1-positive group compared to that in the Wip1-negative group. A univariate analysis and log-rank test indicated that statistically significant association between Wip1 expression and the lower overall survival rate in the patients with glioma. A multivariate analysis also indicated a statistically significant association between increased Wip1 expression and lower overall survival rate. Our results suggest that Wip1 may be related to pathological diagnosis and prognosis evaluation for malignant gliomas.
Dept. of Neurosurgery, The Second Hospital of Hebei Medical University, China.
Chaohui
C
Liang
Erkun
E
Guo
Shengkui
S
Lu
Shuai
S
Wang
Chunsheng
C
Kang
Liang
L
Chang
Liqiang
L
Liu
Guangyu
G
Zhang
Zhendong
Z
Wu
Zongmao
Z
Zhao
Shucheng
S
Ma
Liqun
L
Wang
Bao-Hua
BH
Jiao
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D002648:Child; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D005910:Glioma / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010749:Phosphoprotein Phosphatases / Q000235:genetics* / Q000378:metabolism*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D000071636:Protein Phosphatase 2C; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D055815:Young Adult
D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; C000607456:PPM1A protein, human; C000607457:PPM1B protein, human; C000607458:PPM1D protein, human; C000607460:PPM1G protein, human; D010749:Phosphoprotein Phosphatases; D000071636:Protein Phosphatase 2C